

Results of the TRANSLATE-POPS trial presented

October 31 2013

According to a new study of heart attack patients treated with percutaneous coronary intervention (PCI), free access to platelet function testing had only a modest impact on anti-clotting drug selection and dosing. Findings of the TRANSLATE-POPS trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

While previous [trials](#) have examined [platelet function](#) testing-guided antiplatelet treatment strategies among patients undergoing PCI, little is known regarding how this testing impacts real world practice. The TRANSLATE-POPS trial evaluated whether routine availability of platelet function testing alters clinician selection and dosing of anti-clotting therapy, as well as patient outcomes after [acute myocardial infarction](#) treated with PCI. The primary end point was the rate of in-hospital therapeutic adjustments to anti-clotting therapy.

The prospective, cluster randomized trial randomly assigned sites not already routinely testing platelet function (

Citation: Results of the TRANSLATE-POPS trial presented (2013, October 31) retrieved 25 April 2024 from <https://medicalxpress.com/news/2013-10-results-translate-pops-trial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.